Related references
Note: Only part of the references are listed.Anti-Angiogenesis Therapy in the Vx2 Rabbit Cancer Model with a Lipase-cleavable Sn 2 Taxane Phospholipid Prodrug using alpha(v)beta(3)-Targeted Theranostic Nanoparticles
Dipanjan Pan et al.
THERANOSTICS (2014)
Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles
Hui-fang Zhou et al.
BIOMATERIALS (2012)
Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug
Dipanjan Pan et al.
NANOMEDICINE (2012)
miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc
Zhe Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Phospholipase A2 Biochemistry
John E. Burke et al.
CARDIOVASCULAR DRUGS AND THERAPY (2009)
Discovery of Novel Myc-Max Heterodimer Disruptors with a Three-Dimensional Pharmacophore Model
Gabriela Mustata et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis
Shelton D. Caruthers et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2009)
N-Myc Regulates a Widespread Euchromatic Program in the Human Genome Partially Independent of Its Role as a Classical Transcription Factor
Rebecca Cotterman et al.
CANCER RESEARCH (2008)
The oral absorption of phospholipid prodrugs:: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration
Arik Dahan et al.
JOURNAL OF CONTROLLED RELEASE (2008)
Improved low molecular weight Myc-Max inhibitors
Huabo Wang et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A. novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine:: In-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate
Arik Dahan et al.
JOURNAL OF CONTROLLED RELEASE (2007)
Secretory phospholipase A2 hydrolysis of phospholipid analogues is dependent on water accessibility to the active site
Gunther H. Peters et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells
Che-Pin Lin et al.
ANTI-CANCER DRUGS (2007)
Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs
TL Andresen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Low molecular weight inhibitors of Myc-Max interaction and function
XY Yin et al.
ONCOGENE (2003)
X-ray structures of Myc-Max and Mad-Max recognizing DNA: Molecular bases of regulation by proto-oncogenic transcription factors
SK Nair et al.
CELL (2003)
Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue
J Davidsen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2003)
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts
T Berg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Function and regulation of the transcription factors of the Mye/Max/Mad network
B Lüscher
GENE (2001)
The prognostic importance of c-myc oncogene expression in head and neck melanoma
JS Chana et al.
ANNALS OF PLASTIC SURGERY (2001)
Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27kip1 levels
I D'Agnano et al.
ONCOGENE (2001)
Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases
GM Kraehn et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
